Boston Scientific (BSX) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ResMed (RMD) has outperformed Boston Scientific (BSX) over the past year, losing 20.2% versus a loss of 56.6%. Over five years, BSX leads with a -4.2% price change compared with -11.6% for RMD. Boston Scientific is the larger company by market cap ($60.26 billion vs $31.78 billion), about 1.9 times the size.
On valuation, Boston Scientific trades at a lower forward P/E (12.3x vs 17.1x for ResMed). ResMed pays a dividend yielding 1.06%, while Boston Scientific does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus 14.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSX | RMD |
|---|---|---|
| Share price | $41.58 | $225.98 |
| Market cap | $60.26B | $31.78B |
| 1-day change | -1.45% | +2.40% |
| YTD return | -56.39% | -6.18% |
| 1-year return | -56.64% | -20.23% |
| 5-year return | -4.19% | -11.55% |
| P/E ratio (TTM) | 16.83 | 21.16 |
| Forward P/E | 12.29 | 17.08 |
| EPS (TTM) | $2.47 | $10.68 |
| Dividend yield | 0.00% | 1.06% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $20.07B | $5.65B |
| Revenue growth (YoY) | +19.87% | +9.85% |
| Net income (latest FY) | $2.89B | $1.52B |
| Gross margin | 69.01% | 61.06% |
| Operating margin | 18.00% | 33.37% |
| Net margin | 14.41% | 26.94% |
| 52-week high | $105.65 | $284.05 |
| 52-week low | $41.50 | $180.27 |
| Distance from 52-week high | -60.64% | -20.44% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +44.06% | +10.73% |
| Average volume | 19.71M | 1.34M |
| Shares outstanding | 1.45B | 140.64M |
| Employees | 59,000 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMD has outperformed BSX by 36.4 percentage points over the past year.
- ResMed trades at a higher earnings multiple (21.2x vs 16.8x trailing P/E).
- ResMed offers a meaningfully higher dividend yield (1.06% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus 14.4 cents for Boston Scientific.
- Boston Scientific grew revenue faster in its latest fiscal year (+19.87% vs +9.85%).
About Boston Scientific
BSX stock →Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Health Care · Medical/Dental Instruments · 59,000 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
BSX vs RMD FAQ
Which is bigger, Boston Scientific or ResMed?
Boston Scientific (BSX) is larger, with a market capitalization of $60.26B compared with $31.78B for ResMed (RMD).
Which stock has performed better over the past year, BSX or RMD?
RMD returned -20.23% over the past 12 months, compared with -56.64% for BSX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BSX or RMD?
BSX has the lower trailing P/E at 16.8, versus 21.2 for RMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Boston Scientific or ResMed?
ResMed pays a dividend yielding 1.06%, while Boston Scientific does not currently pay a regular dividend.
Are Boston Scientific and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.